Navidea Envisions a World Where Disease can be Precisely Identified and Treated

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care.

Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases.

Learn More

The Sale of Lymphoseek® to Cardinal Health

Navidea Biopharmaceuticals has sold the North American rights of its Lymphoseek® product to Cardinal Health. Lymphoseek® is used for lymphatic mapping, lymph node biopsy and the diagnosis of metastatic spread to lymph nodes for the staging of cancer.

Read Press Release

Latest Event

Jun 29, 2017

Annual Shareholder Meeting

View All Events

Navidea Biopharmaceuticals, Inc.






Day Range

Year Range